Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
The DOI matches its Crossref record; 307 of the 308 references it cites were found in a registry or an index.
Abstract
The acetylation of histone and non-histone proteins has been implicated in several disease states. Modulation of such epigenetic modifications has therefore made histone deacetylases (HDACs) important drug targets. HDAC3, among various class I HDACs, has been signified as a potentially validated target in multiple diseases, namely, cancer, neurodegenerative diseases, diabetes, obesity, cardiovascular disorders, autoimmune diseases, inflammatory diseases, parasitic infections, and HIV. However, only a handful of HDAC3-selective inhibitors have been reported in spite of continuous efforts in design and development of HDAC3-selective inhibitors. In this Perspective, the roles of HDAC3 in various diseases as well as numerous potent and HDAC3-selective inhibitors have been discussed in detail. It will surely open up a new vista in the discovery of newer, more effective, and more selective HDAC3 inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since HDAC3 can directly regulate cell epigenetic landscape that may subsequently reshape transcriptome profiles (8, 12)”
From Arresting the bad seed: HDAC3 regulates proliferation of different microglia after ischemic stroke (2024) · cites this paper as [12]
Citations
Cites
2 retracted
Items 201–307 of 307
Bardai, F. H., Verma, P., Smith, C., Rawat, V., Wang, L., & D’Mello, S. R. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5831-12.2013 · Cited by 59
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
Batlevi, C. L., Kasamon, Y., Bociek, R. G., Lee, P., Gore, L., Copeland, A., Sorensen, R., Ordentlich, P., Cruickshank, S., Kunkel, L., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.142406 · Cited by 59
Valproic Acid Prevents Penile Fibrosis and Erectile Dysfunction in Cavernous Nerve-Injured Rats
Hannan, J. L., Kutlu, Ö., Stopak, B. L., Liu, X., Castiglione, F., Hedlund, P., Burnett, A. L. “., & Bivalacqua, T. J. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12522 · Cited by 58
Sharma, V., Koul, N., Joseph, C., Dixit, D., Ghosh, S., & Sen, E. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00844.x · Cited by 57
Liu, J., Yu, Y., Kelly, J., Sha, D., Alhassan, A.-B., Yu, W., Maletic, M. M., Duffy, J. L., Klein, D. J., Holloway, M. K., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00462 · Cited by 57
Marson, C. M., Matthews, C. J., Atkinson, S. J., Lamadema, N., & Thomas, N. S. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00545 · Cited by 56
Kuta, R., Larochelle, N., Fernandez, M., Pal, A., Minotti, S., Tibshirani, M., St. Louis, K., Gentil, B. J., Nalbantoglu, J. N., Hermann, A., et al. (2020) · Cell Stress and Chaperones · doi:10.1007/s12192-019-01064-1 · Cited by 56
Thomas, E. (2014) · Pharmaceuticals · doi:10.3390/ph7060634 · Cited by 55
Pinkerneil, M., Hoffmann, M. J., Kohlhof, H., Schulz, W. A., & Niegisch, G. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0444-7 · Cited by 55
HIV-1 Vpr reactivates latent HIV-1 provirus by inducing depletion of class I HDACs on chromatin
Romani, B., Jamil, R. K., Hamidi-Fard, M., Rahimi, P., Momen, S. B., Aghasadeghi, M. R., & Allahbakhshi, E. (2016) · Scientific Reports · doi:10.1038/srep31924 · Cited by 55
Marson, C. M., Matthews, C. J., Yiannaki, E., Atkinson, S. J., Soden, P. E., Shukla, L., Lamadema, N., & Thomas, N. S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400634n · Cited by 54
Magnaghi-Jaulin, L., Éot-Houllier, G., Fulcrand, G., & Jaulin, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3012 · Cited by 54
Nozik-Grayck, E., Woods, C., Stearman, R. S., Venkataraman, S., Ferguson, B. S., Swain, K., Bowler, R. P., Geraci, M. W., Ihida-Stansbury, K., Stenmark, K. R., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00263.2015 · Cited by 54
Liu, X., Wang, J., Li, S., Li, L., Huang, M., Zhang, Y., Liu, Y., Yang, Y., Ding, R., & Ke, Y. (2015) · Cancer Science · doi:10.1111/cas.12684 · Cited by 53
Yan, Y., An, J., Yang, Y., Wu, D., Bai, Y., Cao, W., Ma, L., Chen, J., Yu, Z., He, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708478 · Cited by 53
Cheng, G., Wang, Z., Yang, J., Bao, Y., Xu, Q., Zhao, L., & Liu, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.12.011 · Cited by 53
Chu, Q., Nielsen, T. O., Alcindor, T., Gupta, A. A., Endo, M., Goytain, A., Xu, H., Verma, S., Tozer, R. G., Knowling, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv033 · Cited by 52
Zhang, Y., Yang, P., Chou, C. J., Liu, C., Wang, X., & Xu, W. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300366t · Cited by 52
Targeting HDAC Complexes in Asthma and COPD
Zwinderman, M. R. H., de Weerd, S., & Dekker, F. J. (2019) · Epigenomes · doi:10.3390/epigenomes3030019 · Cited by 52
Chen, Y., He, R., Chen, Y., D'Annibale, M. A., Langley, B., & Kozikowski, A. P. (2009) · ChemMedChem · doi:10.1002/cmdc.200800461 · Cited by 51
Tak, W. Y., Ryoo, B., Lim, H. Y., Kim, D. Y., Okusaka, T., Ikeda, M., Hidaka, H., Yeon, J.-E., Mizukoshi, E., Morimoto, M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0658-x · Cited by 51
Therapeutic potential of selective histone deacetylase 3 inhibition
Zhang, L., Chen, Y., Jiang, Q., Song, W., & Zhang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.072 · Cited by 51
von Tresckow, B., Sayehli, C., Aulitzky, W. E., Goebeler, M., Schwab, M., Braz, E., Krauss, B., Krauss, R., Hermann, F., Bartz, R., et al. (2019) · European Journal of Haematology · doi:10.1111/ejh.13188 · Cited by 50
Comparison of the Deacylase and Deacetylase Activity of Zinc-Dependent HDACs
McClure, J. J., Inks, E. S., Zhang, C., Peterson, Y. K., Li, J., Chundru, K., Lee, B., Buchanan, A., Miao, S., & Chou, C. J. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00321 · Cited by 49
Dirice, E., Ng, R. W. S., Martinez, R., Hu, J., Wagner, F. F., Holson, E. B., Wagner, B. K., & Kulkarni, R. N. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.804328 · Cited by 49
Zhang, J., Xu, Z., Gu, J., Jiang, S., Liu, Q., Zheng, Y., Freedman, J. H., Sun, J., & Cai, L. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00465.2017 · Cited by 49
He, B., Dai, L., Zhang, X., Chen, D., Wu, J., Feng, X., Zhang, Y., Xie, H., Zhou, L., Wu, J., et al. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27661 · Cited by 48
Boissinot, M., Inman, M., Hempshall, A., James, S. R., Gill, J. H., Selby, P., Bowen, D. T., Grigg, R., & Cockerill, P. N. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.07.002 · Cited by 47
Venkatraman, A., Hu, Y.-S., Didonna, A., Cvetanović, M., Krbanjevic, A., Bilesimo, P., & Opal, P. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu081 · Cited by 47
Kim, Y., Eom, S., Kim, K., Lee, Y., Choe, J., Hahn, J. H., Lee, H., Kim, Y.-M., Ha, K., Ro, J. Y., et al. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.11.017 · Cited by 47
Romani, B., Shaykh‐Baygloo, N., Hamidi-Fard, M., Aghasadeghi, M. R., & Allahbakhshi, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.689018 · Cited by 47
Choudhary, V., Olala, L. O., Kagha, K. C., Pan, Z.-Q., Chen, X., Yang, R., Cline, A. E., Helwa, I., Marshall, L. E., Kaddour‐Djebbar, I., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.04.031 · Cited by 47
Ryu, Y., Kee, H. J., Sun, S., Seok, Y. M., Choi, S. Y., Kim, G. R., Kee, S., Pflieger, M., Kurz, T., Kim, H.-S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213186 · Cited by 47
PINK1 positively regulates HDAC3 to suppress dopaminergic neuronal cell death
Choi, H.-K., Choi, Y., Kang, H., Lim, E.-J., Park, S.-Y., Lee, H.-S., Park, J.-M., Moon, J., Kim, Y.-J., Choi, I., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu526 · Cited by 46
Kinzel, O., Llauger-Bufi, L., Pescatore, G., Rowley, M., Schultz-Fademrecht, C., Monteagudo, E., Fonsi, M., Gonzalez Paz, O., Fiore, F., Steinkühler, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9004303 · Cited by 45
Xu, G., Zhu, H., Zhang, M., & Xu, J. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3225 · Cited by 45
Amin, S. A., Adhikari, N., & Jha, T. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0130 · Cited by 45
Self-citationLi, X., Zhang, Y., Jiang, Y., Wu, J., Inks, E. S., Chou, C. J., Gao, S., Hou, J., Ding, Q., Li, J., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.069 · Cited by 44
Hanigan, T. W., Aboukhatwa, S. M., Taha, T. Y., Frasor, J. M., & Petukhov, P. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.015 · Cited by 44
Schmitt, H. M., Schlamp, C. L., & Nickells, R. W. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0059 · Cited by 44
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
Zhang, B., Liu, B., Chen, D., Setroikromo, R., Haisma, H. J., & Quax, W. J. (2019) · Cancers · doi:10.3390/cancers11050645 · Cited by 44
Li, X., Tu, Z., Li, H., Liu, C., Li, Z., Sun, Q., Yao, Y., Liu, J., & Jiang, S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300371t · Cited by 43
Xia, M., Zhao, Q., Zhang, H., Chen, Y., Yuan, Z., Xu, Y., & Zhang, M. (2017) · Neural Plasticity · doi:10.1155/2017/6237351 · Cited by 43
Joshi, A., Barabutis, N., Birmpas, C., Dimitropoulou, C., Thangjam, G. S., Cherian‐Shaw, M., Dennison, J., & Catravas, J. D. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00180.2015 · Cited by 42
Crazzolara, R., Jöhrer, K., Johnstone, R. W., Greil, R., Ofler, R. K., Meister, B., & Bernhard, D. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03955.x · Cited by 42
Xu, Y., Voelter‐Mahlknecht, S., & Mahlknecht, U. (2005) · International Journal of Molecular Medicine · doi:10.3892/ijmm.15.1.169 · Cited by 42
Amin, S. A., Adhikari, N., Kotagiri, S., Jha, T., & Ghosh, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.077 · Cited by 42
Self-citationTherapeutic Potential of Isoform Selective Hdac Inhibitors for the Treatment of Schizophrenia
Weïwer, M., Lewis, M. C., Wagner, F. F., & Holson, E. B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.141 · Cited by 41
Tapadar, S., He, R., Luchini, D. N., Billadeau, D. D., & Kozikowski, A. P. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.058 · Cited by 41
Yin, Y., Zhang, M., Dorfman, R. G., Li, Y., Zhao, Z., Pan, Y., Zhou, Q., Huang, S. H., Zhao, S., Yao, Y., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.457 · Cited by 41
Zhou, Y., Wang, Q., Yang, Q., Tang, J., Xu, C., Gai, D.-W., Chen, X., & Chen, J. (2018) · Virologica Sinica · doi:10.1007/s12250-018-0057-7 · Cited by 41
Zhao, N., Li, S., Wang, R., Xiao, M.-H., Meng, Y., Zeng, C., Fang, J., Yang, J., & Zhuang, S. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.05.006 · Cited by 40
Wasim, L., & Chopra, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.057 · Cited by 40
Gao, X., Shen, L., Li, X., & Liu, J. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7704 · Cited by 40
Villagra, A., Ulloa, N., Zhang, X., Yuan, Z., Sotomayor, E., & Seto, E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701719200 · Cited by 38
Taha, T. Y., Aboukhatwa, S. M., Knopp, R. C., Ikegaki, N., Abdelkarim, H., Neerasa, J., Lu, Y., Neelarapu, R., Hanigan, T. W., Thatcher, G. R. J., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00126 · Cited by 38
He, P., Li, K., Li, S.-B., Hu, T., Guan, M., Sun, F., & Liu, W.-W. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4284 · Cited by 38
Pinz, S., Unser, S., Buob, D., Fischer, P., Jobst, B., & Rascle, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv188 · Cited by 37
Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer
McLeod, A., Stice, J. P., Wardell, S. E., Alley, H. M., Chang, C., & McDonnell, D. P. (2017) · The Prostate · doi:10.1002/pros.23467 · Cited by 36
Thaler, F., Moretti, L., Amici, R., Abate, A., Colombo, A., Carenzi, G. E. A., Fulco, M. C., Boggio, R., Dondio, G. M., Gagliardi, S., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.11.010 · Cited by 35
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma
Moreau, P., Facon, T. T. F., Touzeau, C., Benboubker, L., Delain, M., Badamo-Dotzis, J., Phelps, C. E., Doty, C., Smit, H., Fourneau, N., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1117611 · Cited by 35
Inhibition of Hdac3 as a Strategy for Developing Novel Diabetes Therapeutics
Meier, B. C., & Wagner, B. K. (2014) · Epigenomics · doi:10.2217/epi.14.11 · Cited by 34
Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer
Cui, Z., Xie, M., Wu, Z., & Shi, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.906576 · Cited by 34
Sung, E.-S., Kim, A., Park, J. S., Chung, J., Kwon, M.-H., & Kim, Y. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0521-9 · Cited by 33
Shimony, S. O., Horowitz, N. A., Ribakovsky, E., Rozovski, U., Avigdor, A., Zloto, K., Berger, T., Avivi, I. M., Perry, C., Abadi, U., et al. (2019) · Hematological Oncology · doi:10.1002/hon.2691 · Cited by 33
Selective and Nonselective HDAC8 Inhibitors: a Therapeutic Patent Review
Adhikari, N., Amin, S. A., & Jha, T. (2018) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2018-0019 · Cited by 32
Self-citationMorioka, N., Tomori, M., Zhang, F. F., Saeki, M., Hisaoka‐Nakashima, K., & Nakata, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.11.086 · Cited by 31
Ocasio, C. A., Sansook, S., Jones, R. N., Roberts, J. M., Scott, T. G., Tsoureas, N., Coxhead, P., Guille, M., Tizzard, G. J., Coles, S. J., et al. (2017) · Organometallics · doi:10.1021/acs.organomet.7b00437 · Cited by 31
Tang, S., Cheng, B., Zhe, N., Ma, D., Xu, J., Li, X., Guo, Y., Wu, W., & Wang, J. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000568 · Cited by 31
Terracciano, S., Micco, S. D., Bifulco, G., Gallinari, P., Riccio, R., & Bruno, I. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.022 · Cited by 30
Zhang, J., Henagan, T. M., Gao, Z., & Ye, J. (2011) · Endocrinology · doi:10.1210/en.2010-0828 · Cited by 30
Chen, W.-B., Gao, L., Wang, J., Wang, Y.-G., Dong, Z., Zhao, J., Mi, Q., & Zhou, L. (2016) · Oncotarget · doi:10.18632/oncotarget.11295 · Cited by 30
Nghia, N. A., Hirasawa, T., Kasai, H., Obata, C., Moriishi, K., Mochizuki, K., Koizumi, S., & Kubota, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.010 · Cited by 29
Duncan, C. E., An, M. C., Papanikolaou, T., Rugani, C., Vitelli, C., & Ellerby, L. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-42 · Cited by 29
Ma, Y., Baltezor, M. J., Rajewski, L. G., Crow, J., Samuel, G., Staggs, V. S., Chastain, K. M., Toretsky, J. A., Weir, S. J., & Godwin, A. K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01782-0 · Cited by 29
Zhang, Y., Tuzova, M. N., Xiao, Z. J., Cruikshank, W. W., & David M Center (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.402 · Cited by 28
Designing potential HDAC3 inhibitors to improve memory and learning
Amin, S. A., Adhikari, N., Jha, T., & Ghosh, B. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1477625 · Cited by 28
Self-citationSanchez, S., Lemmens, S., Baeten, P., Sommer, D., Dooley, D., Hendrix, S., & Gou-Fàbregas, M. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.5.437 · Cited by 28
Konsoula, Z., Cao, H., Velena, A., & Jung, M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.11.057 · Cited by 27
Lu, Y., Chia-Hung, C., Tzen, K., Gao, M., Cheng, A., Kulp, S. K., & Cheng, J. C. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.12.022 · Cited by 27
Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways
Zhang, L., Hong, Z., Zhang, R., Sun, X., Yuan, Y., Hu, J. P., & Wang, X. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.07.049 · Cited by 27
Zhang, L., Zhang, Y., Chou, C. J., Inks, E. S., Wang, X., Li, X., Hou, J., & Xu, W. (2013) · ChemMedChem · doi:10.1002/cmdc.201300297 · Cited by 26
Narita, N., Fujieda, S., Tokuriki, M., Takahashi, N., Tsuzuki, H., Ohtsubo, T., & Matsumoto, H. (2005) · Oncogene · doi:10.1038/sj.onc.1208879 · Cited by 26
Histone deacetylase 3 indirectly modulates tubulin acetylation
Bacon, T., Seiler, C., Wolny, M., Hughes, R., Watson, P. J., Schwabe, J. W. R., Grigg, R., & Peckham, M. (2015) · Biochemical Journal · doi:10.1042/bj20150660 · Cited by 26
Zeng, Z., Liao, R., Yao, Z., Zhou, W., Ye, P., Zheng, X., Li, X., Huang, Y., Chen, S., & Chen, Q. (2013) · Gene · doi:10.1016/j.gene.2013.09.123 · Cited by 25
Hamoud, M. M. S., Pulya, S., Osman, N. A., Bobde, Y., Hassan, A. E. A., Abdel‐Fattah, H. A., Ghosh, B., & Ghanim, A. M. (2020) · New Journal of Chemistry · doi:10.1039/d0nj01274b · Cited by 25
Self-citationDifferential Effect of HDAC3 on Cytoplasmic and Nuclear Huntingtin Aggregates
Mano, T., Suzuki, T., Tsuji, S., & Iwata, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111277 · Cited by 24
Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor
Soumyanarayanan, U., Ramanujulu, P. M., Mustafa, N. B., Haider, S. M., Nee, A. H. F., Tong, J. X., Tan, K. S. W., Chng, W. J., & Dymock, B. W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111755 · Cited by 24
DNA methyl transferase I acts as a negative regulator of allergic skin inflammation
Kim, Y., Kim, K., Park, D., Lee, E., Lee, H., Lee, Y., Choe, J., Kim, Y., & Jeoung, D. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.06.010 · Cited by 23
Zang, J., Shi, B., Liang, X., Gao, Q., Xu, W., & Zhang, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.12.001 · Cited by 23
Thaler, F. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.11.3 · Cited by 21
HDAC3 regulates stability of estrogen receptor α mRNA
Oie, S., Matsuzaki, K., Yokoyama, W., Murayama, A., & Yanagisawa, J. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.007 · Cited by 21
Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma
Lombard, D. B., Cierpicki, T., & Grembecka, J. E. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0069 · Cited by 21
Nishimoto, K., Niida, H., Uchida, C., Ohhata, T., Kitagawa, K., Motegi, A., Suda, T., & Kitagawa, M. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0214 · Cited by 21
Shu, J., Li, L., Zhou, L., Qian, J., Fan, Z., Zhuang, L., Wang, L., Jin, R., Yu, H., & Zhou, G.-P. (2017) · Oncotarget · doi:10.18632/oncotarget.17586 · Cited by 19
McCann, C. K., Crawford, N., Majkut, J., Holohan, C., Armstrong, C. W. D., Maxwell, P. J., Ong, C. W., LaBonte, M. J., McDade, S. S., Waugh, D. J. J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1125-5 · Cited by 19
Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis
Zhang, M., Yin, Y., Dorfman, R. G., Zou, T., Pan, Y., Li, Y., Wang, Y., Zhou, Q., Zhou, L., Kong, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19660 · Cited by 18
Yalniz, F., Berdeja, J. G., Maris, M. B., Lyons, R. M., Reeves, J. A., Essell, J. H., Patel, P. A., Sekeres, M. A., Hughes, A. E., Mappa, S., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16173 · Cited by 18
Thaler, F., Varasi, M., Abate, A., Carenzi, G. E. A., Colombo, A., Bigogno, C., Boggio, R., Zuffo, R. D., Rapetti, D., Resconi, A., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.061 · Cited by 17
Histone deacetylase 3 represses HTLV-1 tax transcription
Villanueva, R., Iglesias, A. H., Camelo, S. I., Sanin, L., Gray, S. G., & Dangond, F. (2006) · Oncology Reports · doi:10.3892/or.16.3.581 · Cited by 16
Dissecting HDAC3-mediated tumor progression
Mariadason, J. M. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.6863 · Cited by 16
Abdelkarim, H., Neelarapu, R., Madriaga, A., Vaidya, A. S., Kastrati, I., Karumudi, B., Wang, Y., Taha, T. Y., Thatcher, G. R. J., Frasor, J. M., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700449 · Cited by 14
Spiro[chromane‐2,4′‐piperidine]‐Based Histone Deacetylase Inhibitors with Improved in vivo Activity
Thaler, F., Varasi, M., Carenzi, G. E. A., Colombo, A., Abate, A., Bigogno, C., Boggio, R., Carrara, S., Cataudella, T., Zuffo, R. D., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200024 · Cited by 13
Liu, K., Fu, J., Zhou, N., Yin, W., Yang, Y., Ouyang, S.-X., & Liang, Y. (2019) · Medical Science Monitor · doi:10.12659/msm.916313 · Cited by 13
New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
Reimer, P. (2015) · Cancer Management and Research · doi:10.2147/cmar.s85351 · Cited by 11
Kee, H. J., Kim, G. R., Lin, M. Q., Choi, S. Y., Ryu, Y., Jin, L., Piao, Z. H., & Jeong, M. H. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.0266 · Cited by 9
Discovery of a Novel HDAC3 Selective Inhibitor and its Evaluation in Lymphoma Model
Choi, C., Kim, M., Han, S., Jeon, J., Lee, J. H., Oh, J., Suh, K. H., Suh, D., & Lee, K. (2015) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.10619 · Cited by 2
Research works printed but not linked: 3
- Liu L. T., 2003, Cancer Res., 63, 3069
- Terui T., 2003, Cancer Res., 63, 8948
- Xu Y., 2005, Int. J. Mol. Med., 15, 169
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
“Interestingly, in HPLC-based assay with myristoyl-H3K9 peptide as substrate, SIS17 (25) are slightly less potent than FT895 (24).”
BackgroundMethodInfluentialCarboranes as unique pharmacophores in antitumor medicinal chemistry
Chen, Y., Du, F., Tang, L., Xu, J., Zhao, Y., Wu, X., Li, M., Shen, J., Wen, Q., Cho, C. H., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.005 · Cited by 135
Lanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 112
Self-citationThe role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases
He, R., Liu, B., Geng, B., Li, N., & Geng, Q. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01399-w · Cited by 75
“The unique structure of HDAC3 All class I HDAC enzymes exhibit structural similarity to reduced potassium depenency 3 (RPD3) in yeast, and mainly contain a catalytic core domain and C-and N-terminals [17].”
Metadata
- Authors
- Adhikari, N., Jha, T., & Ghosh, B.
- Affiliations
- Jadavpur University (IN)
- Birla Institute of Technology and Science - Hyderabad Campus (IN)
- Corresponding author
- Jha, Tarun
- Ghosh, Balaram
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-06-23
- Volume
- 64
- Issue
- 13
- Pages
- 8827-8869
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3176448552
- Cited by
- 74
- References
- 308
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 18 · 2023: 15 · 2022: 8 · 2021: 3
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Council of Scientific and Industrial Research (09/096(0966)/2019-EMR-I, CSIR- 37(1722)/19/EMR-II)
- University Grants Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- HDAC3, histone acetylation, non-histone protein acetylation, epigenetic drug targets, cancer, neurodegenerative diseases, diabetes mellitus, obesity, cardiovascular disease, autoimmune disease, inflammatory diseases, parasitic infection, HIV, inhibitor design
- MeSH terms
- Histone Deacetylase 3, Autoimmune Diseases, Cardiovascular Diseases, Diabetes Mellitus, Histone Deacetylases, Humans, Neoplasms, Obesity, HIV Infections, Neurodegenerative Diseases, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.